Came across this article discussing recent advancements in circulating tumor DNA (ctDNA) technology for detecting minimal residual disease (MRD) post-surgery/treatment. Seems like sensitivity is improving, potentially offering a better way to stratify risk and guide adjuvant therapy decisions. Thought folks here, especially those using or considering Signatera/other assays, might find it interesting. Article
It’s definitely becoming more common, Michael. The hope is it allows for earlier detection of recurrence or confirmation of cure, potentially sparing some from unnecessary chemo or catching things sooner if needed.